99 results about "Immune inflammation" patented technology

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F1F0 ATP hydrolase associated disorders, and the like.

The invention belongs to the technical field of medicines, discloses applications of andrographolide derivatives in preparation of medicines preventing and treating hepatic fibrosis, and relates to 15-benzylidene-14-deoxy-11,12-dehydroandrographolide derivatives and 3,19 esterified compounds thereof. Experiments prove that the compounds significantly inhibit human hepatic stellate cell LX-2 metastasis and activation, significantly reduce the fibrosis level of hepatic tissues of rats affected with hepatic fibrosis, reduce contents of extracellular matrix protein (ECM) related components, significantly reduce the level of immune inflammation correlation factors of rats affected with hepatic fibrosis, effectively inhibit immuno-inflammatory responses, inhibit hepatic stellate cell activation in hepatic tissues, and promote collagen degradation. The compounds are used as active components for preparing the anti-hepatic fibrosis medicines, and are efficient and low in toxicity, thus providing a novel medicine route for hepatic fibrosis treatment and prevention, and expanding the optional range of clinical medicine application. The compounds and the applications have good development prospects.

The present invention provides for the treatment, prevention, and / or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

The invention relates to new application of paeonol and derivatives thereof in the pharmacy field. The animal experiment research shows that paeonol and derivatives thereof can obviously relieve or eliminate the inflammatory reaction of the local tissue of the eye with immunologic conjunctivitis, obviously reduce the infiltration of acidophilic cells and the degranulation of mast cells in the conjunctiva tissue, obviously relieve the inflammatory reaction of the anterior segment of the eye with uveitis, reduce the infiltration of inflammatory cells in the vitreous body and retinal tissue, effectively control the non-infectious immune inflammation of the dry eye, and obviously relieve the inflammatory reaction of the animal model eye with chronic conjunctivitis; and the clinical experiment research shows that the paeonol can be used for effectively treating eye diseases such as sclerotitis and the like. The invention provides a medicament for treating eye diseases, which has the advantages of exact curative effect and wide source and is safe and convenient; and the medicament can be combined with one or more pharmaceutically acceptable carriers or excipients to be prepared into a pharmaceutical composition or preparation of the paeonol and derivatives thereof.

The invention relates to a heterocyclic group contained amino-methanol derivative, its salt, its synthetic method and its use, and belongs to the medical field. The heterocyclic group contained aminomethanol derivative and its salt are used for preparing medicines for immune suppression and organ transplant repulsion reaction treatment, or medicines for treating immune inflammation diseases, such as Multiple Sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

The invention provides application of ABT-263 in preparation of a medicine for inhibiting corneal transplantation immunological rejection, and belongs to the technical field of chemical medicines. The invention provides an application of a micromolecular Bcl-2 inhibitor Navitclax(ABT-263) capable of inducing apoptosis in preparation of a product for inhibiting immunological rejection after corneal transplantation. Researches show that the Bcl-2 inhibitor ABT-263 can prolong the survival time of a corneal graft after corneal transplantation, reduce immune inflammatory response in the corneal graft, maintain transparency of the corneal graft and reduce immunological rejection, and can be used for preventing and treating diseases such as immunological rejection after corneal transplantation, corneal endothelial cell decompensation and the like.

The invention discloses an extraction method of falcate dolichos root or leaf glucoside A. The method comprises the following steps: (1) taking falcate dolichos root or leaf herbs, adding alcohol aqueous solution for reflux extraction, wherein the weight of the alcohol aqueous solution is 6-12 times of that of falcate dolichos root or leaf herbs; (2) recovering the falcate dolichos root or leaf extract solution obtained from the step 1 under reduced pressure to alcohol till no alcohol taste exists, and adding water or alcohol to liquid medicine; (3) adding hydrochloric acid into the liquid medicine obtained from the step 2 till the pH value is 1-6, and adding sodium chloride into the liquid medicine till the salt concentration to 0.1-2mol / L; (4) placing the liquid medicine obtained from the step (3) on a macroporous adsorption resin column for separation; (5) cleaning and purifying with alcohol aqueous solution, of which the volume is 4-10 times of the column volume of the macroporous adsorption resin column, eluting with alcohol aqueous solution, of which the volume is 4-10 times of the column volume of the macroporous adsorption resin column, collecting the eluant, and drying to obtain falcate dolichos root or leaf glucoside A. The invention further discloses an extraction method of total saponins of falcate dolichos root or leaf, and the application of the falcate dolichos root or leaf glucoside A, the total saponins of falcate dolichos root or leaf, falcate dolichos root or leaf glucoside A hydrolysate and salt thereof and falcate dolichos root or leaf glucoside A derivate in preparing immune-inflammation resistant drugs.

Disclosed are compositions and methods for the reduction of C5a mediated immune inflammation. The methods, in various aspects, may include the step of administering a C5aR antagonist to a subject in need of such treatment. In one aspect, the subject in need may have a lysosomal acid storage disease. Therapeutic kits and articles of manufacture are also disclosed.

The present invention designs a Mycobacterium smegmatis IL-17A, wherein the Escherichia coli-mycobacterium shuttle expression vector expressing IL-17A gene is expressed in Mycobacterium smegmatis IL-17A; General Microbiology Center of Species Preservation Management Committee, the deposit number is CGMCCNO.4446. The Mycobacterium smegmatis IL-17A of the present invention has the dual function of Mycobacterium smegmatis and IL-17A, so that the recombinant Mycobacterium promotes non-specific anti-infection immunity and inhibits airway immune inflammation mediated by allergens The effect of injury is significantly enhanced, especially in the prevention and control of asthmatic airway injury caused by allergic asthma or respiratory infection.

The invention relates to a specific blocking agent of a Toll-like receptor 9 (TLR9). The blocking agent is a nonmethylated CpG nucleotide sequence segment, the core structure of which is a CGCG nucleotide sequence, and the length of the nonmethylated CpG nucleotide sequence segment is 12-30 nucleotides. The blocking agent can be specifically combined with the TLR9, can block the combination between other irritant aglucons and the TLR9 and inhibit the proinflammatory effect mediated by the receptor, and can be used for the adjuvant treatment of inflammatory resistance and allergy resistance and the preparation of an experiment reagent of immune inflammation.

The invention discloses a yandang mountain acorus calamus root extracting solution and an application thereof in cosmetics. The extracting solution comprises the following components: alpha-asarone, beta-asarone, cis-methylisoeugenol, methyleugenol, calamendiol and acorone, and the cosmetics are an amino acid face cleanser. The amino acid face cleanser is prepared from the following raw materials: a phase A: 20%-23% of water, 0.03%-0.1% of EDTA (Ethylene Diamine Tetraacetic Acid) disodium, 3%-5% of glycerol, 0.3%-0.8% of glycereth-26 and 0.1%-0.3% of xanthan gum; and a phase B: 20%-30% of TEA-cocoyl glutaminate, 4%-6% of C30K, 10%-18% of RunmildTMCOP, 1%-3% of polyglycerol-10, 7%-9% of CHSB, and 1%-3% of PLANTACARE2000UP. The extracting solution has obvious anti-inflammatory activity and acne removal effect, can inhibit the generation of proinflammatory factors, has anti-inflammatory effect on acute, chronic and some immune inflammation models, has strong antibacterial effect on saccharomycetes and propionibacterium acnes, and has obvious inhibition effect on megalosporon, microsporum, aspergillus niger and candida albicans; and the extracting solution is applicable to face cleansing products.

The invention provides an application of peroxy-ergosterol in preparation of a drug for preventing or treating influenza virus infection, and provides a method for separating peroxy-ergosterol from isatis roots simultaneously. The application of a small molecular compound peroxy-ergosterol in preparation of the drug for preventing or treating the influenza virus infection is provided by the invention, so that the effective drug for preventing and treating clinical influenza currently is provided. The inventor finds that peroxy-ergosterol can effectively inhibit influenza virus induced host cells from overexpressing a pattern recognition receptor RIG-I for pathogen recognition, so that effects of abnormal immune inflammation and mediated apoptosis transduced and mediated with pattern recognition receptor downstream signals are inhibited.